The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
Cells that detach from the extracellular matrix (ECM) undergo various forms of cell death, including ferroptosis. Previous studies have demonstrated that prostate cancer (PCa) cells undergo ...
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...
Metformin has been used for decades as one of the most common medicines for type 2 diabetes. Doctors around the world ...
May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...
The National Institute for Health and Care Excellence (NICE) has recommended a new oral treatment for men with untreated hormone-relapsed metastatic prostate cancer. NICE assessed evidence from the ...
Testosterone replacement therapy (TRT) remains controversial in men with a history of prostate cancer due to historical concerns regarding oncologic safety. This scoping review aimed to systematically ...
8.9% of patients on combo had little to no cancer at surgery vs 1% on hormone therapy alone Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results